Medway Community Healthcare Medway NHS Trust Foundation Trust
Medway Clinical Commissioning Group Swale Clinical Commissioning Group

4.6.2 Migraine and Headache

NHS Kent & Medway guidance on the use of Botulinum toxin type A and calcitonin gene-related peptide inhibitors for preventing migraine in adults. Please  Click Here

Migraines and Headaches - Management of Adults with Headaches and Migraines in Primary Care Guidance and Migraine referral Form  Click Here

Topiramate - Topiramate is contraindicated in pregnancy and in women of childbearing potential unless the conditions of a Pregnancy Prevention Programme are fulfilled. For Implementing MHRA Safety Measures in Kent & Medway Click Here

Rimegepant in Acute Migraine
For Kent and Medway Rimegepant Prescribing Guideline for Primary Care Click Here

 
Erenumab (Aimovig®)

This High-Cost Drug has been approved for the following indications: - for preventing migraine in adults -who have at least 4 migraine days per month (initiated by a specialist) as per NICE TA682

For more information and NICE Guidance Click Here Erenumab for preventing migraine NICE Guidance TA682
ICB commissioned - approval via Blueteq


Eptinezumab (Vyepti®)  

This High-Cost Drug has been approved for the following indications: - for for preventing migraine in adults for preventing migraine in adults -who have at least 4 migraine days per month (initiated by a specialist) as per NICE TA871
For more information and NICE Guidance Click Here Eptinezumab for preventing migraine NICE Guidance TA871
ICB commissioned - approval via Blueteq

Fremanezumab (Ajovy®)
This High-Cost Drug has been approved for the following indications: - for preventing migraine in adults for preventing migraine in adults -who have at least 4 migraine days per month (initiated by a specialist) as per NICE TA764
For more information and NICE Guidance Click Here Fremanezumab for preventing migraine NICE Guidance TA764
ICB commissioned - approval via Blueteq


Galcanezumab (Emgality®)

This High-Cost Drug has been approved for the following indications: - for for preventing migraine in adults for preventing migraine in adults -who have at least 4 migraine days per month (initiated by a specialist) as per NICE TA659
For more information and NICE Guidance Click Here Galcanezumab for preventing migraine NICE Guidance TA659
ICB commissioned - approval via Blueteq


Rimegepant
-for prevention of migraine

This Drug has been approved for the following indications: -  for preventing migraine in adults -who have at least 4 migraine days per month (initiated by a specialist) as per NICE TA906
-Acute treatment of migraine with or without aura in adults as per NICE TA919
For more information and NICE Guidance Click Here

Rimegepant for preventing migraine NICE Guidance TA906
ICB commissioned - approval via Blueteq   

 

Pack
12 tablet
2 tablet
4 tablet
6 tablet
Pack
12 tablet
2 tablet
4 tablet
6 tablet
Pack
2 unit dose
Pack
2 unit dose
6 unit dose
Pack
2 pre-filled disposable injection
Pack
12 tablet
2 tablet
4 tablet
6 tablet
Pack
28 tablet
60 tablet
84 tablet
Pack
28 tablet

On formulary for the acute treatment of migraine in adults in accordance with NICE TA919. The Kent and Medway guidelines on the Management of Adults with Headaches and Migraines in Primary Care will be updated in due course, use local Advice and Guidance in the interim.

For Rimegepant Prescribing Guideline for Primary Care & NICE TA919 Click Here
Rimegepant for Acute treatment of migraine with or without aura in adults as per NICE Guidance TA919

Pack
2 tablet
8 tablet

NHS Kent & Medway guidance on the use of Botulinum toxin type A and calcitonin gene-related peptide inhibitors for preventing migraine in adults. Please  Click Here

Pack
1 vial
  • First Line Choice
  • On Formulary
  • Specialist Initiation Only
  • Hospital Only
  • KMPT Initiation Only
  •